pENTR221-BCL2
(Plasmid
#251695)
-
PurposeGateway-adapted BCL2 ORF
-
Depositing Lab
-
Sequence Information
Ordering
| Item | Catalog # | Description | Quantity | Price (USD) | |
|---|---|---|---|---|---|
| Plasmid | 251695 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $89 | |
Backbone
-
Vector backbonepENTR221
- Backbone size w/o insert (bp) 2544
-
Vector typeGateway Donor vector
Growth in Bacteria
-
Bacterial Resistance(s)Kanamycin, 50 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameBCL2 BCL2 apoptosis regulator
-
SpeciesH. sapiens (human)
-
Insert Size (bp)718
-
Entrez GeneBCL2 (a.k.a. Bcl-2, PPP1R50)
Cloning Information
- Cloning method Gateway Cloning
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pENTR221-BCL2 was a gift from Boyi Gan (Addgene plasmid # 251695 ; http://n2t.net/addgene:251695 ; RRID:Addgene_251695) -
For your References section:
Radiotherapy promotes cuproptosis and synergizes with cuproptosis inducers to overcome tumor radioresistance. Lei G, Sun M, Cheng J, Ye R, Lu Z, Horbath A, Huo D, Wu S, Alapati A, Aggarwal S, Xu Z, Mao C, Yan Y, Yao J, Li Q, Chen X, Lee H, Zhuang L, Jiang D, Pataer A, Roth JA, Navin N, Koong AC, You MJ, Lin SH, Gan B. Cancer Cell. 2025 Jun 9;43(6):1076-1092.e5. doi: 10.1016/j.ccell.2025.03.031. Epub 2025 Apr 10. 10.1016/j.ccell.2025.03.031 PubMed 40215978